Clinical trial · Interventional
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Department of Radiation, Sun Yat-sen University
NCT05367206CI-TRIAL-00058376N6CrecruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma \>4 cm in greatest dimension and/or lymph node \>2cm in short axis.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bulky Neoplasm | — | UNRESOLVED | — |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Albumin-Bound Paclitaxel | Drug | Nab-paclitaxel | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- NAC plus RCT
- description
- two circles of NAC with albumin-bound paclitaxel and carboplatin followed by standard chemoradiation with weekly cisplatin plus pelvic radiation
- interventionNames
- Drug: Albumin-Bound Paclitaxel
- Drug: Carboplatin
- type
- NO_INTERVENTION
- label
- RCT
- description
- standard chemoradiation with weekly cispatin plus pelvic radiation
Primary outcomes (1)
- measure
- 3-year progression-free survival ratio
- timeFrame
- up to 3 years
- description
- the time from study randomization to 3 years, the ratio for patients without disease progression nor death.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. pathologically comfirmed : squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix； 2. FIGO (2018 International Federation of Gynecology and Obstetrics) stage IIIC with carcinoma \>4 cm in greatest dimension and/or lymph node \>2 cm in short axis at initial diagnosis. 3. age 18 to 70 years； 4. Eastern Cooperative Oncology Group performance status 0 to 2； 5. adequate organ function. Exclusion Criteria: 1\. not at initial diagnosis; 2. with other kind of tumor. \-
References
Publications (0)
Data not yet available
No reference posted for this study.